Skip to content

Navigating uncertainty in gender incongruence and differences in sex development (DSD)/intersex conditions

Navigating uncertainty in gender incongruence and differences in sex development (DSD)/intersex conditions - UNITE

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON53833
Enrollment
105
Registered
2022-07-27
Start date
2022-06-17
Completion date
Unknown
Last updated
2024-04-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

genderincongruentie differences in sex development/intersex conditions gender incongruence/transgender

Interventions

None listed

Sponsors

Radboud Universitair Medisch Centrum
Lead Sponsor

Eligibility

Age
No minimum to 64 Years

Inclusion criteria

Inclusion criteria: This study consists of three substudies: 1) an interview study, 2) an observation study on clinical consultations, and 3) an observation study on multidisciplinary meetings (MDMs). Below, we provide the inclusion criteria for each study. 1. Interview study: This study concerns four groups: 1) healthcare professionals, 2) children/adolescents with gender incongruence or a DSD/intersex condition, 3) their parents, and 4) (young) adults with a DSD/intersex condition. Below, we provide the inclusion criteria for the interview study for each group: 1) Healthcare professionals working at the Expertise Center Sex & Gender (Radboudumc) or Amsterdam Expertise Center for Atypical sex and gender development (Amsterdam UMC, VUmc & AMC) 2) Children/adolescents with gender incongruence or a DSD/intersex condition between 8 and 18 years old who receive care at one of the two expertise centers (mentioned above) 3) Parents of children/adolescents with gender incongruence or a DSD/intersex condition who receive care at one of the two expertise centers (mentioned above) 4) Adults with a DSD/intersex condition between 18 and 50 years old who received care for this earlier in their lives or still receive medical care 2. Observation study on consultations: This study concerns largely the same groups as the interview study, except for the group of adults with a DSD/intersex condition. Moreover, the minimum age of 8 for children participating in the interview study is not applicable for the observation study, since children younger than 8 may also be part of the video-recorded consultations. Below we provide the inclusion criteria for the observation study for each group: 1) Healthcare professionals working at the Expertise Center Sex & Gender (Radboudumc) or Amsterdam Expertise Center for Atypical sex and gender development (Amsterdam UMC, VUmc & AMC) 2) Children/adolescents with gender incongruence or a DSD/intersex condition between 0 and 18 years old, who receive care at one of the two expertise centers (mentioned above) 3) Parents of children/adolescents with gender incongruence or a DSD/intersex condition who receive care at one of the two expertise centers (mentioned above) 3. Observation study on MDMs: This study concerns the same group of healthcare professionals as those approached for the studies described above: Healthcare professionals working at the Expertise Center Sex & Gender (Radboudumc) or Amsterdam Expertise Center for Atypical sex and gender development (Amsterdam UMC, VUmc & AMC)

Exclusion criteria

Exclusion criteria: -

Design outcomes

Primary

MeasureTime frame
Interview study: insight into the experiences and reflections of healthcare professionals, children/adolescents and their parents with regard to uncertainty in transgender and DSD/intersex care. Observation study consultations: insight into the ways in which different types of uncertainty manifest in clinical consultations, what the interactional consequences of those manifestations are, and whether/how these change in the course of a medical trajectory. Observation study MDMs: insight into the ways in which different types of uncertainty manifest in multidisciplinary meetings, and what the interactional consequences of those manifestations are.

Secondary

MeasureTime frame
N/a.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)